CTS Q1 Earnings Call: Diversified Markets Strengthen as Tariff Uncertainty Weighs on Outlook

Electronic components manufacturer CTS Corporation (NYSE: CTS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $125.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $535 million at the midpoint. Its non-GAAP profit of $0.44 per share was 10.2% below analysts’ consensus estimates.

Is now the time to buy CTS? Find out in our full research report (it’s free).

StockStory’s Take

CTS Corporation’s first quarter results were marked by a stable sales performance, as management pointed to significant growth in diversified end markets such as medical, aerospace, and industrial segments. CEO Kieran O’Sullivan highlighted a 14% increase in diversified market sales, with robust booking activity, especially in medical ultrasound and therapeutic applications. However, transportation-related sales declined due to ongoing challenges in China and commercial vehicle products, reflecting a mixed demand environment across segments.

Looking ahead, the company’s outlook remains cautious given external risks. Management reiterated its full-year revenue and adjusted EPS guidance, noting that continued execution in diversified markets and progress on integration of the SyQwest acquisition will be key. O’Sullivan acknowledged the potential impact of tariffs and geopolitical factors, stating, “If something changes there, that would cause us to adjust,” while emphasizing ongoing mitigation efforts such as pricing adjustments and operational agility.

Key Insights from Management’s Remarks

Despite flat overall revenue, CTS management emphasized several operational shifts and market trends that shaped the quarter. The company’s focus on diversification produced notable gains in non-transportation segments, while external headwinds continued to affect transportation markets.

• Diversified Market Momentum: Sales in medical, aerospace, defense, and industrial end markets grew 14%, with management singling out medical ultrasound and therapeutics for strong order activity and new customer wins.
• Aerospace and Defense Expansion: The integration of the SyQwest acquisition contributed to a 39% increase in aerospace and defense sales, with management noting new orders in sonar, anti-jamming, and sensor applications, as well as a healthy backlog for future quarters.
• Industrial Gradual Recovery: Industrial market sales recovered modestly, supported by demand for EMC filters and sensors. Bookings increased 19% year over year, and management expects further improvement as inventory normalization continues.
• Transportation Market Weakness: Transportation segment sales declined 12%, with management attributing this to soft demand in China and competitive pressures in commercial vehicles. Despite headwinds, new product wins in accelerator modules and vehicle footwell integration were highlighted as future growth drivers.
• Tariff and Cost Mitigation: Management reported minimal short-term tariff impact but remains vigilant, working closely with customers to adapt pricing and logistics. The company is monitoring the geopolitical environment and potential trade policy changes that could affect future demand and manufacturing footprint.

Drivers of Future Performance

CTS management expects continued growth in diversified end markets to offset ongoing softness in transportation, though tariff and geopolitical risks could introduce volatility. The company’s margin outlook is tied to a shift in sales mix and operational initiatives.

• Diversification Driving Margins: Management sees higher-margin diversified markets, particularly medical and aerospace/defense, as key to improving overall operating profitability through the year.
• SyQwest Integration Impact: The recent acquisition is expected to contribute more meaningfully in the second half, aided by government contract seasonality and expanded product offerings.
• Tariff and Geopolitical Risks: The company highlighted uncertainty around tariffs and trade policy as a primary risk. Management is actively working on mitigation strategies, but changes in tariffs or trade agreements, especially related to Mexico and China, could affect both costs and demand.

Top Analyst Questions

• John Franzreb (Sidoti): Asked if strong bookings in diversified markets reflected customer prebuying ahead of tariff costs. Management clarified that medical bookings were for longer-term demand, and prebuying was not broad-based.
• John Franzreb (Sidoti): Inquired about changes in transportation market assumptions. CEO Kieran O’Sullivan noted some prebuying in transportation but stated that guidance assumes stable demand unless conditions change.
• John Franzreb (Sidoti): Sought clarity on how profit is expected to ramp throughout the year given first quarter softness. Management pointed to higher revenue in later quarters, SyQwest seasonality, and improved sales mix as drivers.
• Hendi Susanto (Gabelli Funds): Asked about the company’s manufacturing footprint and exposure to tariffs. Management described regional manufacturing alignment and mitigation levers, including pricing adjustments and logistics options.
• Hendi Susanto (Gabelli Funds): Queried about main drivers for margin improvement. Management cited faster-growing diversified markets and operational efficiency as primary contributors, with SyQwest and product mix changes also playing a role.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be closely monitoring (1) the sustained growth and order momentum in diversified end markets such as medical and aerospace/defense, (2) progress on integrating and scaling SyQwest’s product lines and backlog, and (3) the company’s ability to mitigate the impact of tariffs and geopolitical developments through pricing, logistics, and operational adjustments. Execution on new product launches in transportation and commercial vehicle segments will also be important indicators of recovery.

CTS currently trades at a forward P/E ratio of 20×. Should you double down or take your chips? The answer lies in our free research report.

High-Quality Stocks for All Market Conditions

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.